Status:
COMPLETED
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
Lead Sponsor:
AstraZeneca
Conditions:
Erosive Esophagitis
Reflux Esophagitis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
Eligibility Criteria
Inclusion
- Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years
- Patients must have moderate to severe erosive esophagitis
Exclusion
- Significant gastrointestinal bleeding
- Severe heart, lung, liver or kidney disease
- Esophagitis not related to acid reflux
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00206180
Start Date
June 1 2004
End Date
August 1 2005
Last Update
March 26 2009
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Alabaster, Alabama, United States
2
Research Site
Anaheim, California, United States
3
Research Site
Dinuba, California, United States
4
Research Site
Fresno, California, United States